NO941422L - - Google Patents

Info

Publication number
NO941422L
NO941422L NO941422A NO941422A NO941422L NO 941422 L NO941422 L NO 941422L NO 941422 A NO941422 A NO 941422A NO 941422 A NO941422 A NO 941422A NO 941422 L NO941422 L NO 941422L
Authority
NO
Norway
Prior art keywords
immunogen
disclosed
isolated antibody
antibody immunoreactive
immunoreactive
Prior art date
Application number
NO941422A
Other languages
English (en)
Norwegian (no)
Other versions
NO941422D0 (no
NO317625B1 (no
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27120174&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO941422(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Immunex Corp filed Critical Immunex Corp
Publication of NO941422D0 publication Critical patent/NO941422D0/no
Publication of NO941422L publication Critical patent/NO941422L/no
Publication of NO317625B1 publication Critical patent/NO317625B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/73—Fusion polypeptide containing domain for protein-protein interaction containing coiled-coiled motif (leucine zippers)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
NO19941422A 1991-10-25 1994-04-19 Ligand til CD40 reseptoren, DNA, Vektor, Vertcelle, Fremgangsmate for fremstilling, Protein og Farmasoytisk preparat. NO317625B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US78370791A 1991-10-25 1991-10-25
US80572391A 1991-12-05 1991-12-05
PCT/US1992/008990 WO1993008207A1 (en) 1991-10-25 1992-10-23 Novel cytokine

Publications (3)

Publication Number Publication Date
NO941422D0 NO941422D0 (no) 1994-04-19
NO941422L true NO941422L (cs) 1994-06-27
NO317625B1 NO317625B1 (no) 2004-11-29

Family

ID=27120174

Family Applications (2)

Application Number Title Priority Date Filing Date
NO19941422A NO317625B1 (no) 1991-10-25 1994-04-19 Ligand til CD40 reseptoren, DNA, Vektor, Vertcelle, Fremgangsmate for fremstilling, Protein og Farmasoytisk preparat.
NO19980030A NO320073B1 (no) 1991-10-25 1998-01-05 Antistoffer som binder CD40-L

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO19980030A NO320073B1 (no) 1991-10-25 1998-01-05 Antistoffer som binder CD40-L

Country Status (12)

Country Link
EP (2) EP0897983B1 (cs)
JP (2) JP3308534B2 (cs)
KR (1) KR100283541B1 (cs)
AT (2) ATE239790T1 (cs)
AU (1) AU661360B2 (cs)
CA (2) CA2121798C (cs)
DE (2) DE69233051T2 (cs)
DK (3) DK0667901T4 (cs)
ES (2) ES2227513T5 (cs)
FI (2) FI116850B (cs)
NO (2) NO317625B1 (cs)
WO (1) WO1993008207A1 (cs)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5981724A (en) * 1991-10-25 1999-11-09 Immunex Corporation DNA encoding CD40 ligand, a cytokine that binds CD40
US7405270B2 (en) 1991-10-25 2008-07-29 Immunex Corporation CD40-Ligand lacking native-pattern glycosylation
US5716805A (en) * 1991-10-25 1998-02-10 Immunex Corporation Methods of preparing soluble, oligomeric proteins
US5962406A (en) * 1991-10-25 1999-10-05 Immunex Corporation Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same
US7070777B1 (en) * 1991-11-15 2006-07-04 The Trustees Of Columbia University In The City Of New York Method for inhibiting inflammation with an antibody that binds the 5C8 protein
US5474771A (en) 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
US6472510B1 (en) 1992-02-14 2002-10-29 Bristol-Myers Squibb Company CD40 receptor ligands
US5397703A (en) 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
US5874082A (en) * 1992-07-09 1999-02-23 Chiron Corporation Humanized anti-CD40 monoclonal antibodies and fragments capable of blocking B cell proliferation
WO1994004570A1 (en) * 1992-08-21 1994-03-03 Schering Corporation Cd40 ligand, anti cd40 antibodies, and soluble cd40
US5540926A (en) * 1992-09-04 1996-07-30 Bristol-Myers Squibb Company Soluble and its use in B cell stimulation
EP0612529B1 (en) * 1993-01-22 2000-04-05 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Therapeutic agent for NIDDM
DE69433399T2 (de) * 1993-01-22 2004-10-14 Immunex Corp., Seattle Detektion und behandlung von mutationen in einem gen für einen cd40-liganden
US5869049A (en) * 1993-09-02 1999-02-09 Trustees Of Dartmouth College Methods of inducing T cell unresponsiveness to bone marrow with gp39 antagonists
ES2134954T3 (es) * 1993-09-02 1999-10-16 Dartmouth College Procedimiento de supresion prolongada de la inmunidad humoral.
ZA946765B (en) * 1993-09-02 1996-02-15 Dartmouth College Methods of prolonged suppression of humoral immunity
DK0721346T3 (da) * 1993-09-02 1999-03-22 Dartmouth College Fremgangsmåde til induktion af antigenspecifik T-celletolerance
AU1059095A (en) * 1993-11-24 1995-06-13 Australian National University, The Treatment of viral disease with cd40l peptide
JPH09507074A (ja) * 1993-12-23 1997-07-15 イミュネックス・コーポレーション Ｃｄ４０を発現する腫瘍細胞を特徴とする疾患の予防又は治療方法
US5683693A (en) * 1994-04-25 1997-11-04 Trustees Of Dartmouth College Method for inducing T cell unresponsiveness to a tissue or organ graft with anti-CD40 ligand antibody or soluble CD40
MX9605088A (es) 1994-04-28 1997-08-30 Boehringer Ingelheim Pharma Metodos para proliferar y diferenciar celulas b y sus usos.
DE69622259T2 (de) * 1995-03-01 2003-03-27 Immunex Corp., Seattle Cd40 bindendes protein zur stimulierung der immunantwort
AU2556195A (en) 1995-03-13 1996-10-02 Regents Of The University Of Michigan, The CD40 binding compositions and methods of using same
CA2222914C (en) * 1995-06-07 2002-04-02 Immunex Corporation Novel cd40l mutein
EP0833847B1 (en) * 1995-06-22 2003-09-24 Biogen, Inc. Crystals of fragments of cd40 ligand and their use
US6001358A (en) 1995-11-07 1999-12-14 Idec Pharmaceuticals Corporation Humanized antibodies to human gp39, compositions containing thereof
US6440418B1 (en) 1995-11-07 2002-08-27 Idec Pharmaceuticals Corporation Methods of treating autoimmune diseases with gp39-specific antibodies
US6340459B1 (en) 1995-12-01 2002-01-22 The Trustees Of Columbia University In The City Of New York Therapeutic applications for the anti-T-BAM (CD40-L) monoclonal antibody 5C8 in the treatment of reperfusion injury in non-transplant recipients
JP2000512541A (ja) * 1996-06-14 2000-09-26 ユニバーシティ オブ ワシントン 吸収力が向上した差違抽出装置
AU705647B2 (en) * 1996-07-10 1999-05-27 Immunex Corporation Method of activating dendritic cells
US6017527A (en) * 1996-07-10 2000-01-25 Immunex Corporation Activated dendritic cells and methods for their activation
US7070771B1 (en) * 1996-12-09 2006-07-04 Regents Of The University Of California Methods of expressing chimeric mouse and human CD40 ligand in human CD40+ cells
US6271349B1 (en) 1996-12-23 2001-08-07 Immunex Corporation Receptor activator of NF-κB
ES2144386T5 (es) 1996-12-23 2012-12-07 Immunex Corporation Ligando para el activador del receptor de NF-kappa b, el ligando es miembro de la superfamilia de TNF
CA2328140C (en) 1998-05-14 2012-03-13 Immunex Corporation Method of inhibiting osteoclast activity
ES2422231T3 (es) * 1998-10-23 2013-09-09 Kirin Amgen Inc Péptidos miméticos de trombopoyetina diméricos que se unen al receptor MP1 y que tienen actividad trombopoyética
US7300774B1 (en) 1999-12-09 2007-11-27 The Regents Of The University Of California Multimeric fusion proteins of the TNF superfamily ligands
WO2000063395A1 (en) * 1999-04-16 2000-10-26 F. Hoffmann-La Roche Ag Nucleic acids encoding cd40/cd40l chimeric polypeptides, methods for their production and uses thereof
EP1067194A1 (en) * 1999-04-16 2001-01-10 F. Hoffmann-La Roche Ag Vectors containing a gene coding for CD40 and/or CD40L under the control of a cytokine-inducible promoter which is a human acute phase amyloid A gene promoter. Methods for their production and uses thereof
US6482411B1 (en) 1999-08-27 2002-11-19 Board Of Regents, The University Of Texas System Methods of reducing bone loss with CD40 ligand
GB9927757D0 (en) * 1999-11-25 2000-01-26 Kennedy Rheumatology Inst Treatment of autoimmune diseases
AU2001251612A1 (en) 2000-04-14 2001-10-30 Millennium Pharmaceuticals, Inc. Roles of jak/stat family members in tolerance induction
EP1284747A2 (en) 2000-05-12 2003-02-26 Beth Israel Deaconess Medical Center, Inc. Compositions and methods for achieving immune suppression
AU2001296545A1 (en) 2000-10-02 2002-04-15 Chiron Corporation Methods of therapy for b-cell malignancies
AU2002221780A1 (en) * 2000-10-31 2002-05-15 F.Hoffmann-La Roche Ag Nucleic acids encoding cd40/cd40l chimeric polypeptides, methods for their production and uses thereof
KR101038585B1 (ko) 2001-06-26 2011-06-03 암젠 인코포레이티드 Ｏｐｇｌ 에 결합하는 항체, 이의 조성물 및 이의 제조방법
US6586245B2 (en) 2001-07-18 2003-07-01 Isis Pharmaceuticals, Inc. Antisense modulation of CD40 ligand expression
EP1414483A1 (en) * 2001-07-31 2004-05-06 Serono Genetics Institute S.A. Agonists and antagonists of moxifin for the treatment of metabolic disorders
DK1434871T3 (en) 2001-09-20 2017-04-18 Immunex Corp SELECTION OF CELLS EXPRESSING HETEROMERIC POLYPEPTIDES
US7786282B2 (en) 2001-12-06 2010-08-31 The Regents Of The University Of California Nucleic acid molecules encoding TNF-α ligand polypeptides having a CD154 domain
US7495090B2 (en) 2002-05-23 2009-02-24 The Regents Of The University Of California Nucleic acids encoding chimeric CD154 polypeptides
RS20050614A (en) 2003-02-14 2007-12-31 Biogen Idec Ma Inc., An expression cassette and vector for transient or stable expression of exogenous molecules
CA2575838A1 (en) 2004-07-26 2006-03-30 Biogen Idec Ma Inc. Anti-cd154 antibodies
US8513008B2 (en) 2004-10-07 2013-08-20 Argos Therapeutics, Inc. Mature dendritic cell compositions and methods for culturing same
US8822223B2 (en) 2004-10-07 2014-09-02 Argos Therapeutics, Inc. Mature dendritic cell compositions and methods for culturing same
KR101370253B1 (ko) 2004-10-22 2014-03-05 암젠 인크 재조합 항체의 재접힘 방법
JP5878682B2 (ja) 2006-09-13 2016-03-08 アッヴィ・インコーポレイテッド 細胞培養の改善
EP2500414A1 (en) 2006-09-13 2012-09-19 Abbott Laboratories Cell culture improvements
EP2066339B1 (en) 2006-09-18 2014-08-13 The Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancing immune responses
ES3006441T3 (en) 2007-09-14 2025-03-18 Amgen Inc Homogeneous antibody populations
BRPI0818736A2 (pt) 2007-10-30 2017-06-13 Univ Arkansas composições e métodos para intensificar imunorrepostas à bactéria flagelada
AU2008318357B2 (en) 2007-11-01 2015-01-22 The Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancing immune responses to eimeria
BRPI0906490A2 (pt) 2008-01-15 2015-07-14 Abbott Lab Vetores de expressão de mamífero melhorados e uso dos mesmos
PL2501822T3 (pl) 2009-11-17 2017-12-29 E. R. Squibb & Sons, L.L.C. Sposoby zwiększenia produkcji białek
UA110024C2 (uk) 2010-01-21 2015-11-10 Вакцинний вектор і спосіб посилення імунної відповіді
BR112012031211A2 (pt) 2010-06-09 2018-01-30 Univ Arkansas métodos e vacina para reduzir a infecção causada pelo campylobacter
SG10202109925TA (en) 2013-02-14 2021-10-28 Univ Arkansas Compositions and methods of enhancing immune responses to eimeria or limiting eimeria infection
US10023608B1 (en) 2013-03-13 2018-07-17 Amgen Inc. Protein purification methods to remove impurities
EA033538B1 (ru) 2013-03-15 2019-10-31 Univ Arkansas Композиции и способы усиления иммунного ответа на кишечные патогены
CN107921087A (zh) 2015-07-16 2018-04-17 百欧肯治疗有限公司 治疗癌症的组合物及方法
SG10201913275QA (en) 2015-08-05 2020-02-27 Janssen Biotech Inc Anti-cd154 antibodies and methods of using them
WO2017083604A1 (en) 2015-11-12 2017-05-18 Amgen Inc. Triazine mediated pharmacokinetic enhancement of therapeutics
JP7467027B2 (ja) 2016-05-03 2024-04-15 ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ アーカンソー 免疫刺激性ポリペプチドおよび抗原性ポリペプチドを含む酵母ワクチンベクター並びにそれを使用する方法
WO2017197098A1 (en) 2016-05-11 2017-11-16 Amgen Inc. Direct selection of cells expressing high levels of heteromeric proteins using glutamine synthetase intragenic complementation vectors
AU2018223822A1 (en) * 2017-02-27 2019-07-11 Shattuck Labs, Inc. CSF1R-based chimeric proteins
CA3054127A1 (en) 2017-02-27 2018-08-30 Shattuck Labs, Inc. Tigit- and light-based chimeric proteins

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL104684A0 (en) * 1992-02-14 1993-06-10 Bristol Myers Squibb Co The cd40cr receptor and ligands therefor
US5540926A (en) * 1992-09-04 1996-07-30 Bristol-Myers Squibb Company Soluble and its use in B cell stimulation

Also Published As

Publication number Publication date
EP0667901A4 (en) 1995-06-22
JPH10150994A (ja) 1998-06-09
CA2312667A1 (en) 1993-04-29
JPH07504083A (ja) 1995-05-11
NO941422D0 (no) 1994-04-19
DE69233402T3 (de) 2009-06-25
AU661360B2 (en) 1995-07-20
EP0667901B1 (en) 2004-08-18
CA2121798C (en) 2007-07-24
NO320073B1 (no) 2005-10-17
DE69233051T2 (de) 2004-03-11
DE69233402T2 (de) 2005-09-15
JP3308534B2 (ja) 2002-07-29
DE69233402D1 (de) 2004-09-23
DK0667901T3 (da) 2004-12-27
ATE239790T1 (de) 2003-05-15
FI941837A0 (fi) 1994-04-20
FI941837L (fi) 1994-05-30
FI981765A0 (fi) 1998-08-17
FI116828B (fi) 2006-03-15
EP0667901A1 (en) 1995-08-23
EP0667901B2 (en) 2008-10-15
JP2877788B2 (ja) 1999-03-31
CA2121798A1 (en) 1993-04-29
EP0897983A2 (en) 1999-02-24
ES2227513T3 (es) 2005-04-01
DE69233051D1 (de) 2003-06-12
DK0897983T3 (da) 2003-08-11
ATE274055T1 (de) 2004-09-15
NO317625B1 (no) 2004-11-29
FI981765L (fi) 1998-08-17
DK0667901T4 (da) 2008-11-10
ES2198025T3 (es) 2004-01-16
ES2227513T5 (es) 2009-04-01
NO980030L (no) 1998-01-05
EP0897983A3 (en) 1999-03-17
AU3122693A (en) 1993-05-21
NO980030D0 (no) 1998-01-05
WO1993008207A1 (en) 1993-04-29
CA2312667C (en) 2002-11-19
KR100283541B1 (ko) 2001-03-02
DK0822199T3 (da) 2004-12-27
FI116850B (fi) 2006-03-15
HK1019343A1 (en) 2000-02-03
EP0897983B1 (en) 2003-05-07

Similar Documents

Publication Publication Date Title
NO941422L (cs)
GB2222695B (en) Optical seeker with rosette scanning
AU5567990A (en) Rectified intraocular lens
EP0340779A3 (en) Optical quantum interference device
GB8802220D0 (en) Intraocular lens
DE68916079D1 (de) Intraokulare Linse.
HU896517D0 (en) Optical transistor
EP0469853A3 (en) Light guide
AU586607B2 (en) Device for scanning a radiation-reflecting information surface with optical radiation
EP0507213A3 (en) Light transmitter
GB2226246B (en) Intraocular lens
TW198026B (cs)
ES2054986T3 (es) N-arilacion de isatinas.
DE3765979D1 (de) Intraokulare linse mit verminderter blendwirkung.
DE69104049D1 (de) Mechanisch betätigte bremse mit automatischer justierung.
IT223115Z2 (it) Bruciatore a "rampete" con combustione cosiddetta iperstechiometrica
AU6861691A (en) Valve guide relining sleeve
GB9102177D0 (en) Photo diode
AU1205192A (en) Novel thyroid antigen
CA65789S (en) Handle for adjusting the position of a light
AU657865B2 (en) Light emitting diode scanner
KR890020199U (ko) 팩시밀리의 자동 급지장치
CS909588A1 (en) Connection for control valve's extreme positions automatic scanning
NO894118D0 (no) Fremgangsmaate for regulering av en tresliper.
GR880100752A (cs)

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees